WHAT IS CLAIMED IS:

1. A topical pharmaceutical formulation comprising:

a) 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, a pharmaceutically acceptable salt, or a hydrate or a solvate thereof;

b) from about 5% (w/w) to about 15% (w/w) propylene glycol;

c) butylated hydroxytoluene;

d) edetate calcium disodium;

e) mono- and di- glycerides;

f) paraffin wax; and

g) white petrolatum.

2. The topical pharmaceutical formulation of claim 1 comprising:

a) from about 3. 1% (w/w) to about 2% (w/w) 5-(4-cyanophenoxy)-1,3 dihydro-1-hydroxy-2,1-benzoxaborole;

b) from about 5% (w/w) to about 15% (w/w) propylene glycol USP;

c) 4. 1% (w/w) butylated hydroxytoluene;

d) 5. 0035% (w/w) edetate calcium disodium;

e) 7% (w/w) mono- and di- glycerides NF;

f) 5% (w/w) paraffin wax; and

g) 76.8965% (w/w) white petrolatum.

3. The topical pharmaceutical formulation of claim 2 consisting of:

a) about 2% (w/w) 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof;

b) about 9% (w/w) propylene glycol USP;

c) about 0.1% (w/w) butylated hydroxytoluene;

d) about 0.0035% (w/w) edetate calcium disodium;

e) about 7% (w/w) mono- and di- glycerides NF, wherein between 40% and 55% is said monoglyceride;

f) about 5% (w/w) paraffin wax; and

g) about 76.8965% (w/w) white petrolatum.

4. Use of the topical pharmaceutical formulation of any one of claims 1 to 3 in the manufacture of a medicament for decreasing the release of a cytokine and/or a chemokine.

5. Use of the topical pharmaceutical formulation of any one of claims 1 to 3 in the manufacture of a medicament for treating a topical inflammatory-related condition in an animal.

6. The use of claim 5, wherein the inflammatory-related condition is psoriasis.

7. The use of claim 5, wherein the inflammatory-related condition is atopic dermatitis.

8. Use of the topical pharmaceutical formulation of any one of claims 1 to 3 in the manufacture of a medicament for treating atopic dermatitis in a human.

9. The use of claim 8 wherein the medicament is for administration to an affected area of the human on a twice daily basis.

10. The use of claim 9 wherein the medicament is for administration over a period of about 28 days.

11. The use of claim 8 wherein the medicament further comprises or is for administration in combination with a second active agent.

12. The use of claim 11 wherein the second active agent is a JAK kinase inhibitor such as Tofacitinib, JTE-052, Baricitinib, or Upadacitinib.

13. A topical pharmaceutical formulation comprising:

a) 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, a pharmaceutically acceptable salt, or a hydrate or a solvate thereof;

b) from about 5% (w/w) to about 15% (w/w) propylene glycol;

c) butylated hydroxytoluene;

d) edetate calcium disodium;

e) mono- and di- glycerides;

f) paraffin wax; and

g) white petrolatum;

for use as a medicament.